Otsuka Pharmaceutical and Bristol-Myers Squibb announced that the FDA approved the supplemental NDA for the atypical antipsychotic Abilify (aripiprazole) for the treatment of schizophrenia in adolescents aged 13-17 years. The FDA first approved Abilify for the treatment of schizophrenia in adults on November 15, 2002.
Allergan said the FDA has approved Combigan (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5%, an alpha adrenergic receptor agonist with a beta adrenergic receptor inhibitor, for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP.
